BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 16208307)

  • 21. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
    Braga MF; Leiter LA
    Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of type 2 diabetes.
    Yale JF
    Int J Clin Pract Suppl; 2000 Oct; (113):35-9. PubMed ID: 11965830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials.
    Haffner SM
    Int J Clin Pract Suppl; 2002 Jul; (129):33-9. PubMed ID: 12166604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for the prevention of type 2 diabetes.
    Pfohl M; Schatz H
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S240-9. PubMed ID: 11460574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin for prevention of type 2 diabetes.
    Hess AM; Sullivan DL
    Ann Pharmacother; 2004; 38(7-8):1283-5. PubMed ID: 15150378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies to prevent type 2 diabetes.
    Abuissa H; Bel DS; O'keefe JH
    Curr Med Res Opin; 2005 Jul; 21(7):1107-14. PubMed ID: 16004680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive therapy for diabetes through influence on innate immune system.
    Li ZZ; Liu JB; Li L; Jiao L; Chen L
    Med Hypotheses; 2009 Jun; 72(6):675-6. PubMed ID: 19264419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of type 2 diabetes--an overview].
    Qvigstad E
    Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3047-50. PubMed ID: 15586184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
    Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G;
    Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.